Recombinant MVA virus, and the use thereof
AssigneeGSF-Forschungszentrum fur Umwelt und Gesenudheit GmbH
InventorsGerd Sutter, Marion Ohlmann, Volker Erfle
Life of this patent
Estimating the term…
Abstract
The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.
Claims33
A recombinant Modified Vaccinia Ankara (MVA) virus containing and capable of expressing at least one foreign gene inserted at a site of a naturally occurring deletion within the MVA genome, wherein the site of the naturally occurring deletion is not site III.
A recombinant Modified Vaccinia Ankara (MVA) virus containing and capable of expressing an Human Immunodeficiency Virus (HIV) nef gene inserted into the MVA genome.
A recombinant Modified Vaccinia Ankara (MVA) virus containing and capable of expressing a human tyrosinase gene inserted into the MVA genome.
A recombinant Modified Vaccinia Ankara (MVA) virus containing and capable of expressing at least one foreign gene inserted at a site of a naturally occurring deletion within the MVA genome, wherein the site of the naturally occurring deletion is selected from the group consisting of:
- site I, site II, site IV, site V and site VI.
A recombinant Modified Vaccinia Ankara (MVA) virus containing and capable of expressing at least one foreign gene inserted at deletion site II of the MVA virus.
Dependencies are inferred from the claim text.